{"nctId":"NCT01178125","briefTitle":"A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy","startDateStruct":{"date":"2010-08"},"conditions":["Contraception","Female Contraception"],"count":2858,"armGroups":[{"label":"DR-102","type":"EXPERIMENTAL","interventionNames":["Drug: DR-102"]}],"interventions":[{"name":"DR-102","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sexually active at risk for pregnancy\n* Agreement to use study oral contraceptive therapy as their only method of birth control during the study\n* History of regular spontaneous menstrual cycles or withdrawal bleeding episodes\n* Others as dictated by protocol\n\nExclusion Criteria:\n\n* Any contraindication to the use of oral contraceptives\n* Pregnancy or plans to become pregnant in the next 14 months\n* Smoker and age greater than or equal to 35 years\n* Others as dictated by protocol","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI) and the 7-day rule (a standardized process for calculating pregnancy rates). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-102 or \\> 7 days after stopping the combination desogestrel/ethinyl estradiol (DSG/EE) or ethinyl estradiol (EE) treatment of DR-102.The PI is defined as number of contraceptive failures per 100 women-years of exposure: (100)\\*(total number of pregnancies)\\*(13)/(total number of 28-day cycles). Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":null},{"groupId":"OG001","value":"2.35","spread":null},{"groupId":"OG002","value":"2.90","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs","description":"AEs summarized are those that began or worsened after treatment with investigational product (IP). An AE is any untoward medical occurrence in a subject or clinical investigation subject participating in a clinical study and which does not necessarily have to have a causal relationship with this treatment or clinical study. Severity of AEs was assessed as mild, moderate or severe. A severe AE was defined as incapacitating, with inability to perform usual activity. An AE was defined as treatment-related when there is reasonable possibility that the AE was caused by or attributed to the IP and/or a causal relationship cannot be ruled out. An SAE was defined as one that meets any one of the following criteria: fatal or life-threatening; requires or prolongs in-patient hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1778","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"608","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Endometrial Biopsy Classification Results for Endometrial Tissue/Glands at Baseline and Endpoint","description":"A subset of study participants agreed to have baseline and endpoint (Week 51/Early Withdrawal) endometrial biopsies. Results were provided for assessment of endometrial tissue/glands. Atrophic: scant or moderate amount of tissue, consists of tiny strips and wisps of surface endometrium or small tubular glands with scant or absent luminal secretions. Inactive: tubular glands lined by epithelial cells with mild pseudostratified and elongated nuclei. Proliferative: tubular or elongated glands lined by cells with elongated, dense, pseudostratified nuclei. Secretory: glands are tortuous or coiled with subnuclear vacuolation, secretion, and intraluminal tufts. Hyperplasia: proliferative type of glands showing glandular crowding with irregular shapes and sizes of enlargement, budding, and branching. Menstrual: glandular and stromal breakdown with fibrin thrombi in small vessels, condensed and collapsed stroma, and necrotic debris.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"All Users Life-Table Estimates of Pregnancy Rates Based on 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the thirteen 28-day treatment cycles.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0004","spread":null},{"groupId":"OG001","value":"0.0005","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0013","spread":null},{"groupId":"OG001","value":"0.0010","spread":null},{"groupId":"OG002","value":"0.0028","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0031","spread":null},{"groupId":"OG001","value":"0.0031","spread":null},{"groupId":"OG002","value":"0.0028","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0073","spread":null},{"groupId":"OG001","value":"0.0070","spread":null},{"groupId":"OG002","value":"0.0091","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0078","spread":null},{"groupId":"OG001","value":"0.0070","spread":null},{"groupId":"OG002","value":"0.0125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0088","spread":null},{"groupId":"OG001","value":"0.0082","spread":null},{"groupId":"OG002","value":"0.0125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0104","spread":null},{"groupId":"OG001","value":"0.0094","spread":null},{"groupId":"OG002","value":"0.0163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0132","spread":null},{"groupId":"OG001","value":"0.0120","spread":null},{"groupId":"OG002","value":"0.0202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0161","spread":null},{"groupId":"OG001","value":"0.0153","spread":null},{"groupId":"OG002","value":"0.0202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0184","spread":null},{"groupId":"OG001","value":"0.0174","spread":null},{"groupId":"OG002","value":"0.0243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0190","spread":null},{"groupId":"OG001","value":"0.0181","spread":null},{"groupId":"OG002","value":"0.0243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0209","spread":null},{"groupId":"OG001","value":"0.0195","spread":null},{"groupId":"OG002","value":"0.0287","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0247","spread":null},{"groupId":"OG001","value":"0.0240","spread":null},{"groupId":"OG002","value":"0.0287","spread":null}]}]}]},{"type":"PRIMARY","title":"Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI) and the 7-day rule (a standardized process for calculating pregnancy rates). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-102 or \\> 7 days after stopping the combination DSG/EE or EE treatment of DR-102.The PI is defined as number of contraceptive failures per 100 women-years of exposure: (100)\\*(total number of pregnancies)\\*(13)/(total number of 28-day cycles). Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":null},{"groupId":"OG001","value":"2.59","spread":null},{"groupId":"OG002","value":"3.23","spread":null}]}]}]},{"type":"PRIMARY","title":"Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI) and the 7-day rule (a standardized process for calculating pregnancy rates). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-102 or \\> 7 days after stopping the combination DSG/EE or EE treatment of DR-102.The PI is defined as number of contraceptive failures per 100 women-years of exposure: (100)\\*(total number of pregnancies)\\*(13)/(total number of 28-day cycles). Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets. Compliant use: did not skip 2 or more consecutive pills, had an overall compliance with IP administration of at least 80%, and did not use a prohibited medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null},{"groupId":"OG001","value":"1.79","spread":null},{"groupId":"OG002","value":"3.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the thirteen 28-day treatment cycles. Compliant use: did not skip 2 or more consecutive pills, had an overall compliance with IP administration of at least 80%, and did not use a prohibited medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0015","spread":null},{"groupId":"OG001","value":"0.0009","spread":null},{"groupId":"OG002","value":"0.0047","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0038","spread":null},{"groupId":"OG001","value":"0.0037","spread":null},{"groupId":"OG002","value":"0.0047","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0063","spread":null},{"groupId":"OG001","value":"0.0046","spread":null},{"groupId":"OG002","value":"0.0154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0063","spread":null},{"groupId":"OG001","value":"0.0046","spread":null},{"groupId":"OG002","value":"0.0154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0063","spread":null},{"groupId":"OG001","value":"0.0046","spread":null},{"groupId":"OG002","value":"0.0154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0072","spread":null},{"groupId":"OG001","value":"0.0057","spread":null},{"groupId":"OG002","value":"0.0154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0102","spread":null},{"groupId":"OG001","value":"0.0080","spread":null},{"groupId":"OG002","value":"0.0224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0152","spread":null},{"groupId":"OG001","value":"0.0139","spread":null},{"groupId":"OG002","value":"0.0224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0163","spread":null},{"groupId":"OG001","value":"0.0139","spread":null},{"groupId":"OG002","value":"0.0298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0163","spread":null},{"groupId":"OG001","value":"0.0139","spread":null},{"groupId":"OG002","value":"0.0298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0174","spread":null},{"groupId":"OG001","value":"0.0152","spread":null},{"groupId":"OG002","value":"0.0298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0208","spread":null},{"groupId":"OG001","value":"0.0191","spread":null},{"groupId":"OG002","value":"0.0298","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of On-Drug Pregnancies in All Users, by Body Weight Decile Groups Using the 7-Day Rule","description":"Crude pregnancy rate is defined as the percentage of on-drug pregnancies per number of participants in each body weight decile (weight range, in kilograms). The 7-day rule is a standardized process for calculating pregnancy rates. Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of On-Drug Pregnancies in Typical-Use, by Body Weight Decile Groups Using the 7-Day Rule","description":"Crude pregnancy rate is defined as the percentage of on-drug pregnancies per number of participants in each body weight decile (weight range, in kilograms). The 7-day rule is a standardized process for calculating pregnancy rates. Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of On-Drug Pregnancies in Compliant-Use, by Body Weight Decile Groups Using the 7-Day Rule","description":"Crude pregnancy rate is defined as the percentage of on-drug pregnancies per number of participants in each body weight decile (weight range, in kilograms). The 7-day rule is a standardized process for calculating pregnancy rates. Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets. Compliant use: did not skip 2 or more consecutive pills, had an overall compliance with IP administration of at least 80%, and did not use a prohibited medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of On-Drug Pregnancies in All Users, by Body Mass Index (BMI) Decile Groups Using the 7-Day Rule","description":"Crude pregnancy rate is defined as the percentage of on-drug pregnancies per number of participants in each body mass index (BMI) decile (BMI range, in kg/m\\^2). The 7-day rule is a standardized process for calculating pregnancy rates. Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of On-Drug Pregnancies in Typical-Use, by Body Mass Index (BMI) Decile Groups Using the 7-Day Rule","description":"Crude pregnancy rate is defined as the percentage of on-drug pregnancies per number of participants in each body mass index (BMI) decile (BMI range, in kg/m\\^2). The 7-day rule is a standardized process for calculating pregnancy rates. Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of On-Drug Pregnancies in Compliant-Use, by Body Mass Index (BMI) Decile Groups Using the 7-Day Rule","description":"Crude pregnancy rate is defined as the percentage of on-drug pregnancies per number of participants in each body mass index (BMI) decile (BMI range, in kg/m\\^2). The 7-day rule is a standardized process for calculating pregnancy rates. Seven-day rule: a pregnancy was considered \"on drug\" if the date of conception was on or after the date of first dose of investigational product (IP), but no more than 7 days after the last tablet was taken; last tablet included combination hormonal or EE tablets. Compliant use: did not skip 2 or more consecutive pills, had an overall compliance with IP administration of at least 80%, and did not use a prohibited medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":2765},"commonTop":["Nasopharyngitis","Upper respiratory infection","Sinusitus","Headache","Nausea"]}}}